Recent advances with Prevent of Mother-to-Child Transmission (PMTCT) and Early Infant Diagnosis (EID) programs due to Option B+ and at birth testing have created challenges with specificity of EID testing and false positive result reporting. GHIG was commissioned to work with WHO to better understand the magnitude of this issue and if further guidance was needed with the WHO guidelines. As a result, GHIG contributed to the better defining of a threshold for and EID indeterminate range and improved diagnosis.
